Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EVIOEVIO -98.00% Days Sales Outstanding is 21.41 as of Jun. 2020.
EVIO's average Accounts Receivable for the
three
months ended in Jun. 2020 was $0.14 Mil. EVIO's Revenue for the
three
months ended in Jun. 2020 was $0.60 Mil.
Hence, EVIO's Days Sales Outstanding for the
three
months ended in Jun. 2020 was 21.41.
The historical rank and industry rank for EVIO's Days Sales Outstanding or its related term are showing as below:
EVIO's Days Sales Outstanding is not ranked *
in the Drug Manufacturers industry.
Industry Median: 71.885 * Ranked among companies with meaningful Days Sales Outstanding only.
EVIO's Days Sales Outstanding
increased
from Jun. 2019 (18.81) to Jun. 2020 (21.41).
EVIO (OTCPK:EVIO) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
EVIO Days Sales Outstanding Related Terms
EVIO Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for EVIO's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EVIO vs VCBD, ACCA, LITH: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, EVIO's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EVIO Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, EVIO's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where EVIO's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EVIO (EVIO) has a Days Sales Outstanding of 21.41 as of Jun. 2020. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on EVIO and its competitors.
Is EVIO's Days Sales Outstanding too high?
EVIO's current Days Sales Outstanding is 21.41. The Drug Manufacturers industry median Days Sales Outstanding is 71.89. EVIO's value of 21.41 is 70.2% below this industry median.
How does EVIO's Days Sales Outstanding compare to VCBD and ACCA?
EVIO's Days Sales Outstanding of 21.41 can be compared against companies in the Drug Manufacturers industry. The industry median Days Sales Outstanding is 71.89. EVIO's value of 21.41 is 70.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.89, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EVIO's current Days Sales Outstanding of 21.41 is 70.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on EVIO and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EVIO's current Days Sales Outstanding is 21.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EVIO stock overvalued right now?
EVIO (EVIO) has a current Days Sales Outstanding of 21.41. The current Days Sales Outstanding is 21.41 and 70.2% below the Drug Manufacturers industry median of 71.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For EVIO (EVIO), the current Days Sales Outstanding is 21.41 as of Jun. 2020. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EVIO Inc is a Colorado corporation and a diversified holding company. Its subsidiaries provide analytical testing and advisory services to the emerging legalized cannabis industry. The Company performs analytical testing for cannabis and cannabis-derived products, including hemp and CBD products. Its current operations also include pharmaceutical, environmental, stability, and analytical testing, as well as residential and commercial construction and investments, with operations in the United States and Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVIO has been successfully added to your 
